Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
Clinical management of infective endocarditis (IE) is expected to become more difficult with the emergence of Staphylococcus aureus with reduced susceptibility to vancomycin (SARV) in the United States and worldwide. We report the strain characterization and treatment of a patient with SARV IE.
Woods
Christopher W
CW
Clinical Microbiology, Durham Veterans Administration Medical Center, Durham, NC 27705, USA. woods004@mc.duke.edu
Cheng
Allen C
AC
Fowler
Vance G
VG
Moorefield
Mary
M
Frederick
Joyce
J
Sakoulas
George
G
Meka
Venkata G
VG
Tenover
Fred C
FC
Zwadyk
Peter
P
Wilson
Kenneth H
KH
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects*; D017211:Treatment Failure; D014481:United States; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; D014640:Vancomycin